Istiratumab
Product Specifications
UNSPSC Description
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3].
Target Antigen
EGFR; IGF-1R
Type
Inhibitory Antibodies
Related Pathways
JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/istiratumab.html
Solubility
10 mM in DMSO
Smiles
[Istiratumab]
References & Citations
[1]Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87. |[2]Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. |[3]Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9(1):16832.
Shipping Conditions
Room temperature
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99672/Istiratumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99672/
Clinical Information
Phase 2
CAS Number
1509928-04-4
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
NB200-598JF646 0.1 mL
Mouse Monoclonal RNA Polymerase II/POLR2A Antibody (4H8) [Janelia Fluor 646]
Ask
View Details